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Abstract 
 
Osteosarcoma (OS) represents 3.4% of all childhood cancers with overall survival of 70% not 
improving in 30 years. The consistent surface overexpression of insulin-like growth factor-2 
receptor (IGF2R) has been reported in commercial and patient-derived xenograft (PDX) OS cell 
lines. We aimed to assess efficacy and safety of treating PDX and commercial OS tumors in mice 
with radiolabeled antibody to IGF2R. IGF2R expression on human commercial lines 143B and 
SaOS2 and PDX lines OS-17, OS-33 and OS-31 was evaluated by FACS. The biodistribution and 
microSPECT/CT imaging with 111Indium-2G11 mAb was performed in 143B and OS-17 tumor-
bearing SCID mice and followed by radioimmunotherapy (RIT) with 177Lutetium-l2G11 and 
safety evaluation. All OS cell lines expressed IGF2R. Biodistribution and microSPECT/CT 
revealed selective uptake of 2G11 mAb in 143B and OS17 xenografts. RIT significantly slowed 
down the growth of OS17 and 143B tumors without local and systemic toxicity. This study 
demonstrates the feasibility of targeting IGF2R on OS in PDX and sets the stage for further 
development of  RIT of OS.  
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
Acknowledgements 
 
Firstly, I would like to express my sincere and deep gratitude to my advisor Dr. Kate Dadachova 
for the continuous support of my Master’s study and related research, for her patience, motivation, 
and immense knowledge. Her guidance helped me in all the time of research and writing of this 
thesis. I could not have imagined having a better advisor and mentor for my Master’s study.  
 
My sincere thanks to all my committee members Dr. Chris Phenix, Dr. Maruti Uppalapati for their 
enthusiastic encouragement and valuable feedback all through my research work. I would also take 
this opportunity to thank Dr. Ildiko Badea Graduate Chair of my committee for his insightful 
comments throughout my course.  
 
I would like to thank all my lab members Dr. Kevin Allen, Mackenzie Malo, Dr. Rubin Jao, Dr. 
Wojciech Dawicki, Dr. Muath Helal, Dr. Ravendra Garg, Kienna Mills and Connor Frank for all 
their help and valuable advice during my research program.  
 
The College of Pharmacy and Nutrition at the University of Saskatchewan has been a second home 
for me, and I would like to appreciate the support and encouragement I have received from my 
friends and colleagues throughout my time here.    
 
I would like this opportunity to thank my wonderful housemates who supported me emotionally 
throughout due to being so far away from home. 
 
Finally, I would like to thank my family: my parents and my sister and my boyfriend for supporting 
me spiritually and encouraging me throughout my Master’s thesis program and my life in general.   
 
 
 
 
 
 
 iv 
TABLE OF CONTENTS 
 
PERMISSION TO USE .............................................................................................i 
ABSTRACT……………...........................................................................................ii 
ACKNOWLEDGEMENTS.......................................................................................iii 
TABLE OF CONTENTS  
LIST OF TABLES.....................................................................................................vi 
 
LIST OF FIGURES...................................................................................................vii 
 
LIST OF ABBREVIATIONS.....................................................................................x 
   
1. INTRODUCTION...................................................................................................1 
 
2. LITERATURE REVIEW........................................................................................4 
2.1 Cancer....................................................................................................................4 
2.2 Bone Cancer...........................................................................................................5  
2.3 Types of Bone Cancer............................................................................................5 
2.3.1 Primary bone tumors…………………………………………………………...6 
2.3.2  Secondary bone tumors......................................................................................6 
2.3.3Carcinomas...........................................................................................................6 
2.3.4 Germ cell tumors.................................................................................................7 
2.4 Osteosarcoma.........................................................................................................7 
2.4.1 Site of disease……………………………………………………………..........7 
2.4.2 Age……………………………………………………………………..............7 
2.4.3 Gender…………………………………………………………………….........................................8 
2.4.4 Diagnosis of  Osteosarcoma…………………………………………................8 
2.4.5 Potential therapeutic targets for the treatment of osteosarcoma..........................8 
2.4.6 Prognosis and survival of patients with osteosarcoma........................................9 
2.5 Treatments for metastatic osteosarcoma...............................................................10  
2.5.1 Targeted drug delivery.......................................................................................11 
2.5.2 Nuclear medicine...............................................................................................11 
 v 
2.5.3 Radionuclide therapy......................................................................................11 
2.5.4 Radioimmunotherapy.....................................................................................12 
2.6 Nuclear imaging methods .................................................................................13 
2.6.1 Positron emission tomography (PET).............................................................13 
2.6.2 Single photon emission computed tomography (SPECT)...............................14 
2.6.3 Internalization of antibodies into cancer cells.................................................14 
3. HYPOTHESIS......................................................................................................15  
3.1  OBJECTIVES....................................................................................................15 
4. MATERIALS AND METHODS..........................................................................16 
5. RESULTS..............................................................................................................23 
6.0  CONCLUSION...................................................................................................46  
6.1  DISCUSSION.....................................................................................................47 
REFERENCES..........................................................................................................50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
LIST OF TABLES 
 
TABLE 2.1 TYPES OF CANCER……………………………………………….4 
TABLE 2.2  BONE CANCER SURVIVAL..........................................................5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
LIST OF FIGURES  
 
FIGURE 2.1 SCHEMATIC DIAGRAM OF TUMOR TISSUE PENETRATION RANGE FOR 
INTERNAL RADIOTHERAPY.............................................................................................13 
 
FIGURE 2.2 TYPICAL MOLECULAR IMAGING INSTRUMENTS AND IMAGES 
REPRESENTATIVE OF EACH MODALITY......................................................................14 
 
FIGURE 5.1.1 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON 143B CELL 
LINE........................................................................................................................................24  
 
FIGURE 5.1.2 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON SAOS2 
CELL LINE.............................................................................................................................24    
 
FIGURE 5.1.3 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON OS-33 CELL 
LINE........................................................................................................................................24           
 
FIGURE 5.1.4 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON OS-31 CELL 
LINE........................................................................................................................................24    
 
FIGURE 5.1.5 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON OS-17 CELL 
LINE........................................................................................................................................24    
 
FIGURE 5.2 AVERAGE MEDIAN IGF2R  EXPRESSION VALUE CALCULATED FOR 
EACH CELL LINE ON THE BASIS OF THE VALUES OBTAINED IN THE FLOW 
CYTOMETRY EXPERIMENTS..............................................................................................25 
FIGURE 5.3 BINDING OF CONJUGATED AND UNCONJUGATED ANTIBODY 2G11 TO 
OS-17 CELLS............................................................................................................................26 
 
FIGURE 5.4 BINDING OF CONJUGATED AND UNCONJUGATED ANTIBODY 2G11 TO   
143B CELLS..............................................................................................................................27  
 viii 
 
FIGURE 5.5 BIODISTRIBUTION OF 111IN – LABELED MONOCLONAL ANTIBODIES IN 
OS-17 XENOGRAFTS AT 48 HOURS POST ANTIBODY ADMINISTRATION...................29 
 
FIGURE 5.6 BIODISTRIBUTION OF 111IN – LABELED MONOCLONAL ANTIBODIES IN 
OS-17 XENOGRAFTS AT 24 HOURS POST ANTIBODY ADMINISTRATION...................30 
 
FIGURE 5.7 BIODISTRIBUTION OF 111IN – LABELED MONOCLONAL ANTIBODIES IN 
143B XENOGRAFTS AT 48 HOURS POST ANTIBODY ADMINISTRATION.....................31 
 
FIGURE 5.8 BIODISTRIBUTION OF 111IN – LABELED MONOCLONAL ANTIBODIES IN 
143B XENOGRAFTS AT 24 HOURS POST ANTIBODY ADMINISTRATION.....................32 
 
FIGURE 5.9 microSPECT IMAGING OF OS17 TUMOR-BEARING SCID MICE INJECTED 
WITH 111INDIUM-CHXA” -2G11................................................................................................33 
 
FIGURE 5.10 microSPECT IMAGING OF 143B TUMOR-BEARING SCID MICE INJECTED 
WITH 111INDIUM-CHXA” -2G11................................................................................................34 
 
FIGURE 5.11  microSPECT IMAGING OF HEALTHY SCID MICE WITH  111INDIUM-CHXA”  
-2G11 mAb.....................................................................................................................................35 
 
FIGURE 5.12 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON K7M2 CELL 
LINE AT 1 μg/μL CONCENTRATION................................................................................35-36 
 
FIGURE 5.13 FLOW CYTOMETRY DETECTION OF IGF2R EXPRESSION ON K7M2 CELL 
LINE AT 5 μg/μL CONCENTRATION......................................................................................36 
 
FIGURE 5.14 RADIOIMMUNOTHERAPY OF OS TUMOR-BEARING SCID MICE: a) 143B 
TUMORS; b) OS17 TUMORS. THE MICE WERE INJECTED INTRAPERITONIALLY (IP) 
EITHER 80 μCi 177Lu-2G11, OR 80 μCi 177Lu-MOPC-21, OR UNLABELED (COLD) 2G11, OR 
 ix 
WAS LEFT UNTREATED. A GROUP OF 143B TUMOR BEARING MICE WERE ALSO 
GIVEN 80 μCi 213Bi-2G11........................................................................................................37-38                                                                     
 
FIGURE 5.15 HEMATOLOGIC TOXICITY WAS EVALUATED IN 143B TUMOR BEARING 
MICE TREATED WITH 177Lu-2G11 AND  UNTREATED AFTER 
RADIOIMMUNOTHERAPY. A) WHITE BLOOD CELLS (WBC), B) RED BLOOD CELLS 
(RBC) AND C) PLATELETS (PLT) WERE ANALYZED AFTER 1 WEEK USING THEs 
AUTOMATED BLOOD ANALYZER. ..................................................................................38 
 
FIGURE 5.16 HEMATOLOGIC TOXICITY WAS EVALUATED IN OS-17 TUMOR 
BEARING MICE TREATED WITH 177Lu-2G11 AND  UNTREATED AFTER 
RADIOIMMUNOTHERAPY. A) WHITE BLOOD CELLS (WBC), B) RED BLOOD CELLS 
(RBC) AND C) PLATELETS (PLT) WERE ANALYZED AFTER 1 WEEK USING THE 
AUTOMATED BLOOD ANALYZER....................................................................................39 
 
FIGURE 5.17 EVALUATION OF THE LIVER AND KIDNEY TOXICITY FOR THE 143B 
TUMOR BEARING MICE:  A) ALANINE AMINOTRANSFERASE (ALT); B) ASPARTATE 
AMINOTRANSFERASE (AST);  C) CREATININE ; D) BLOOD UREA NITROGEN (BUN) 
AND OS-17 TUMOR BEARING MICE: E) ALANINE AMINOTRANSFERASE (ALT) F) 
ASPARTATE AMINOTRANSFERASE (AST) G) CREATININE H) BLOOD UREA 
NITROGEN (BUN) .................................................................................................................39-41 
 
FIGURE 5.18 INTERNALIZATION ASSAY- 143B CELLS STAINED WITH 2G11...........42 
 
FIGURE 5.19 INTERNALIZATION ASSAY- 143B CELLS STAINED WITH MOPC-21....42 
 
FIGURE 5.20 GRAPHICAL REPRESENTATION OF THE INTERNALIZATION OF THE 
IGF2R SPECIFIC 2G11 MONOCLONAL ANTIBODY INTO THE 143B CELLS.................43 
 
 x 
FIGURE 5.21 CONCENTRATION DEPENDENT INTERNALIZATION OF THE IGF2R 
SPECIFIC 2G11 MONOCLONAL ANTIBODY INTO THE 143B 
CELLS.........................................................................................................................................44 
 
FIGURE 5.22 BIODISTRIBUTION OF 225Ac – LABELED IgG A AT 10 MOLAR 
EQUIVALENTS EXCESS CONCENTRATION OF DOTA.....................................................45 
 
FIGURE 5.23 BIODISTRIBUTION OF 225Ac – LABELED IgG A AT 109 MOLAR 
EQUIVALENTS EXCESS CONCENTRATION OF DOTA.....................................................46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
LIST OF ABBREVIATIONS 
 
RIT                            Radioimmunotherapy  
OS                             Osteosarcoma  
GEP-NETS               Gastroenteropancreatic neuroendocrine tumors 
TRT                          Targeted Radionuclide Therapy 
IGF2R                       Insulin-like growth factor- 2 receptor 
SNP                           Single Nucleotide Polymorphism 
EBRT                        External beam radiation therapy 
CIHR                         Canadian Institutes of Health Research  
WHO                         World Health Organization   
HER                           Human epidermal growth factor receptor 
PDGFR                      Platelet-derived growth factor receptor 
FGFR                         Fibroblast growth factor receptor 
VEGFR                      Vascular endothelial growth factor receptor 
EGFR                         Epidermal growth factor receptor 
mAb                           Monoclonal Antibody  
LDH                           Lactate Dehydrogenase  
LET                            Linear energy transfer  
MRI                            Magnetic resonance imaging 
CT                              Computed tomography 
SPECT                       Single Photon Emission Computed Tomography 
PET                            Positron Emission Tomography 
FDG                           Fluorodeoxyglucose 
ADC                           Antibody Drug Conjugate 
SCID                          Severe combined immunodeficiency  
MEM/EBSS               Minimum Essential Medium  
CHXA                      (R)-2-Amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-
1,2-diamine-pentaacetic acid 
BCA                           Bifunctional chelating agent 
SG-iTLC                    Silica gel instant thin layer chromatography 
 xii 
ATCC                        American Type Culture Collection 
FACS                         Fluorescence-activated cell sorting  
PBS                            Phosphate buffered saline  
FBS                            Fetal Bovine Serum 
IP                                Intraperitoneal  
XUHS-M                    Extra Ultra High Sensitivity Mouse 
AST                            Aspartate aminotransferase 
ALT                            Alanine aminotransferase 
BUN                            Blood Urea Nitrogen  
EPR                             Enhanced permeability and retention 
DOTA                         Tetraxetan 
225Ac                            Actinium-225 
177Lu                            Lutetium-177  
IgG                              Immunoglobulin G  
PDX                            Patient Derived Xenografts   
188Re                            Rhenium-188  
Ab                               Antibody  
SSTR1                         Somatostatin Receptor 1                       
 
 
 
 
 
 
 
 
 
 
 1 
 
1.0 Introduction 
 
Standard care for patients 
Osteosarcoma is a high-grade primary skeletal malignancy characterized by spindle cells of 
mesenchymal origin depositing immature osteoid matrix. [1,2] It is the most common type of 
cancer that arises in bones, and it is usually found at the end of long bones. However, the common 
site of metastasis occurs in the lungs with the bone being the second most common site of distant 
disease. It ranges from low grade tumors that only require surgery to high tumors that require an 
aggressive treatment regimen. The disease is generally treated with a combination of therapies that 
include either surgery, chemotherapy and radiation therapy. In addition, patients that have high 
number of high-grade tumors receive neo-adjuvant therapy before surgery. Through surgery, it is 
possible to remove the tumor safely when located on the bone or the joint and restore the patient 
to a fully functional life. [3]  After surgery, the percentage of tumor necrosis is measured to check 
if any additional treatment is needed. If such a situation arises, drugs are chosen for additional 
chemotherapy treatment which could last until a few months. However, a pediatric oncology group 
raised concerns regarding the possibility that if a large tumor is present it could lead to resistant 
cells or an increase in micro-metastatic disease during neoadjuvant chemotherapy. [4] Treatments 
options such as radiation therapy use high energy rays or particles to kill cancer cells. However, 
osteosarcoma cells are not easily killed by radiation. [5] Therefore, radiation therapy may not be 
widely used in osteosarcoma treatment. Nevertheless, it has shown to be effective when a tumor 
is difficult to remove through surgery or when some tumor cells continue to reside after surgery. 
[3] The treatment option of chemotherapy is often administered after the radiation. This 
importance of chemotherapeutic response in patients affected with osteosarcoma was emphasized 
by the effectiveness of radiation therapy. [6] It was shown that it is possible to control 
osteosarcoma by giving standard doses of radiation in spite of radiation sensitivity.  Bone seeking 
radioactive drugs such as samarium-153 or radium-233 are known to slow down the tumor growth 
and even help treat symptoms such as pain in patients affected with advanced osteosarcoma. These 
drugs are helpful especially when the cancer has spread to all the bones however there are major 
side effects to using these drugs such as the blood cell counts decrease drastically which could 
increase the risk for bleeding or infections. [5] Despite of all these treatment options and good 
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prognosis, the benefit of improved quality and function of life must be measured minutely against 
the potential side effects of the drug treatments, risk of relapse or the development of additional 
malignancies. [6] Hence depending on the extent, grade and location of the cancer there are several 
different treatment options for osteosarcoma. For the more debilitating kinds of osteosarcoma such 
as (metastatic osteosarcoma and recurrent osteosarcoma) that are difficult to treat, novel therapies 
may be a good option. While chemotherapy drugs are effective for treating osteosarcoma, in some 
cases the drugs are not as effective as the cancer becomes resistant to the regimen over time. As 
alternative options, research is in progress towards discovering newer types of drugs that could 
attack the cancer cells in different ways. Some common examples are immunotherapy and targeted 
therapy. Recent regulatory approvals of Xofigo for treatment of prostate cancer metastasized to 
the bone and Lutathera for treatment of somatostatin receptor-positive gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs) attests the great potential and promise of Targeted 
Radionuclide Therapy (TRT). Radioimmunotherapy, a subset of TRT has shown great promise as 
well since drugs such as Zevalin where approved for treatment of non-hodgkin’s lymphoma over 
a decade ago along with the treatment regimen being successfully employed for a number of 
clinical trials. [7,8]  
Osteosarcoma is the most common non-hematologic primary bone malignancy. [9,10] It has been 
reported that it is the most common primary malignant bone tumor and the fifth most common 
primary malignancy among adolescents and young adults. [11] About 900 new cases are reported 
within the Unites States per year (American Cancer Society) representing about 3.4 % of all 
childhood cancers. [12] Unfortunately, overall survival remains stagnant at approximately 70%, 
and treatment has not evolved in a meaningful way in over 30 years. [13, 14] Regardless of therapy, 
patients who exhibit overt metastatic disease continue to suffer dismal outcomes, with metastases 
to the lungs and to the bone portending an overall survival less than 40% and 20% respectively. 
Osteosarcoma demonstrates tremendous genetic variability [15] precluding the use of more 
conventional targeted therapies and illustrating the need for alternate approaches.  
Thus, there is a need for alternative novel treatment approaches for osteosarcoma. It has been 
demonstrated that insulin-like growth factor- 2 receptor (IGF2R) has been over-expressed across 
a panel of Osteosarcoma cell lines. [16] Moreover, a single nucleotide polymorphism (SNP) within 
a haplotype block in IGF2R was previously linked to an increased osteosarcoma risk. [17] 
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Although IGF2R is expressed normally across various tissue types, the constant over-expression 
in Osteosarcoma suggests that it may serve as a valuable therapeutic target. 
Targeted radionuclide therapy (TRT) delivers cytocidal radiation in the form of alpha- or beta- 
particle emitting radionuclides to the tumor with high precision, thus avoiding many of the side 
effects associated with external beam radiation therapy (EBRT). Recent regulatory approvals of 
223Radium chloride (Xofigo) for treatment of prostate cancer metastasized to the bone, and of 
177Lutetium-labeled peptide (Lutathera) for treatment of somatostatin receptor-positive 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs), attests to the great promise and 
flexibility of TRT. Radioimmunotherapy (RIT) is a subset of TRT and is a method of delivering 
cytotoxic radiation in a targeted approach where an antigen-specific antibody is bound to either an 
alpha or beta- emitting radioisotope. [7,8] RIT was regulatory approved more than a decade ago 
for refractory and recurrent non-Hodgkin’s lymphoma (Zevalin) [18] as well as has been 
successfully employed in a number of clinical trials [19]. It allows systemic administration, 
antibody-mediated specificity, and physical cytocidal damage in a manner which is well-tolerated 
by the patients.  
Recently Dadachova’s laboratory demonstrated that IGF2R can be a potential target for RIT of 
osteosarcoma. [20] The purpose of this study is to investigate a novel therapy for Osteosarcoma, 
using RIT targeted to IGF2R.  Lutetium-177, a powerful β-emitter with a physical half-life of 6.6 
days has been selected for radiolabeling the IGF2R- specific antibody. 
 
My contribution to the field of radioimmunotherapy (RIT) of osteosarcoma.  
When I joined Dadachova’s lab to work on the project of RIT of osteosarcoma – the antibody 
which binds to both human and murine IGF2R – 2G11 – has just become available commercially. 
Having this antibody in hand allowed me not only to evaluate the RIT of osteosarcoma in mice 
bearing osteosarcoma xenografts, but also to measure any possible toxic effects of RIT on the 
healthy tissues which express IGF2R. The results of my experiments on the comprehensive 
evaluation of RIT of osteosarcoma in mice helped our laboratory to obtain the CIHR grant  to take 
this project further and to evaluate the comparative oncology in companion dogs with 
osteosarcoma. 
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2.0 LITERATURE REVIEW 
 
2.1 Cancer 
 
Cancer is a group of diseases that involves abnormal cell growth and have potential to spread to 
other parts of the body. A cancerous (malignant) tumor is a group of cancer cells that can grow 
into and destroy nearby tissue. It can also metastasize to other parts of the body. There are several 
signs and symptoms associated with cancer but they are not specific to cancer. The most common 
ones being an abnormal growing mass, sudden weight loss, abnormal bleeding etc. [21] According 
to WHO cancer statistics in the year 2007, cancer was responsible for 7.9 million deaths, resulting 
in approximately 13% of all deaths worldwide. It is expected that the number will increase to over 
11 million deaths by 2030. [22] 
 
 Cancers are classified by the type of cell that the tumor cells originated from. 
 
TUMOR TYPE ORIGIN CANCER 
Carcinoma Epithelial cells Breast, lung, prostrate, 
pancreas and colon 
Sarcoma Connective tissues (bone, 
cartilage, fat, nerve) 
Osteosarcoma, 
chondrosarcoma and lipo 
sarcoma 
Lymphoma and Leukemia Hematopoietic (blood 
forming) cells  
Hodgkin lymphoma, Non-
Hodgkin lymphomas 
Blastoma Immature “precursor cells or 
embryonic tissue  
Nephroblastoma, 
medulloblastoma and 
retinoblastoma 
Germ cell tumor Pluripotent cells (testicle and 
ovary) 
Seminoma and dysgerminoma 
  TABLE 2.1 Types of Cancer.  
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2.2 Bone Cancer 
 
Bone cancers start in the cells of the bone or cartilage and are mostly called sarcomas. This kind 
of cancer that originates in the bone is rare and is known as the primary bone cancer. This cancer 
is more common in children and young adults than in older people. The secondary bone cancer or 
bone metastases spread to the bone from other parts of the body and are more common in older 
adults. This kind of cancer is more common than primary bone cancer. In Canada, the five-year 
relative survival for primary bone cancer is 68% [11], whereas the average five-year survival rate 
in the United States after being diagnosed with bone and joint cancer is 67%.[23]  
 
  TABLE 2.2 Bone Cancer Survival  
 
TUMOR TYPE 5 YEAR SURVIVAL RATE, 
% 
Chondrosarcoma (most common adult bone cancer) 80   
Osteosarcoma, localized (stages 1,2 and 3) 60 to 80  
Osteosarcoma, metastatic to lungs only (stage 4) 40   
Osteosarcoma, metastatic to other organs (stage 4) 15 to 30  
 
 
  Canadian Cancer Society (2017) 
 
 
2.3 Types of Bone Cancer 
 
Bone tumors may be classified as “primary tumors” and “secondary tumors” depending on the 
origin of site. The primary bone tumors originate in the bone or from bone-derived cells and tissues 
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whereas the secondary bone tumors originate in other sites of the body and spread or metastasize 
the bone. The secondary bone tumors are most commonly carcinomas of breast, lung and prostate. 
 
 
2.3.1 Primary bone tumors 
 
Primary bone tumors can be divided into two categories 1) Benign tumors 2) Malignant tumors. 
In etiology, the benign bone tumors can be neoplastic, developmental, traumatic, infectious or 
inflammatory. They account for 0.2% of all tumors in humans. [11] The primary tumors, both 
malignant and benign are most commonly located in the distal femur and around the knee joint. 
Primary bone tumors are an uncommon malignancy but are primarily found in young people. It is 
the sixth most common tumor form in children, however it is the third most frequent in adolescents 
and young adults. [11] Some examples of benign bone tumors are osteoma, osteochondroma, 
osteoblastoma, fibrous dysplasia etc. Malignant primary bone tumors include osteosarcoma, 
chondrosarcoma, Ewing’s sarcoma, fibro sarcoma, angiosarcoma etc.  Multiple myeloma is a 
hematologic malignant tumor which frequently presents as one or more bone tumors. It is a very 
common primary bone cancer.  
 
2.3.2 Secondary bone tumors 
 
Metastatic cancer is the most common type of bone malignancy, which metastasizes to the liver, 
lungs, breast and prostate first and then targets the skeleton. [24,25] The malignant bone lesions 
are characterized by abnormal bone formation, bone loss or even both. [25,26] These tumors that 
originate in the soft tissues may secondarily involve bones through direct invasion.  
 
2.3.3 Carcinomas 
 
Carcinomas are a type of cancer that originates from epithelial cells. Carcinomas of prostate, 
breasts, lungs, thyroid and kidneys are the most common types of cancer that metastasize to the 
bone. 
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2.3.4 Germ cell tumors 
 
The most common being teratoma are often present and originate in the midline of the sacrum, 
coccyx or both. 
 
2.4 Osteosarcoma 
 
Osteosarcoma is the most common non-hematologic primary bone malignancy. [9,10] It is a 
malignant tumor that originates from primitive bone-forming mesenchymal cells. [27] It has been 
reported that it is the most common primary malignant bone tumor and the fifth most common 
primary malignancy among adolescents and young adults. [28] An observation was made that 
approximately 1,000 new cases are seen per year in North America and a similar number in Europe. 
[29] Several important pathogenic roles of p53, RB and mdm2 genes have been reported already, 
however, the role and pathogenesis of osteosarcoma in bone microenvironment has not yet been 
fully understood. [30] The overall 5-year survival rate has plateaued at approximately 70% with 
no meaningful improvement in over 30 years. [10, 28, 13, 31] Patients with metastatic disease have 
poor outcomes, with 35-40% survival rate. Thus, there is a need for alternative novel treatment 
approaches for osteosarcoma. [32] Understanding the biological mechanisms that govern the 
osteosarcoma growth at the molecule level is highly important and essential for developing new 
strategies of treatment. 
 
 
2.4.1 Site of disease  
Osteosarcoma occurs in any bone of the body but usually in areas of the long bones of the 
extremities such as the distal femur and proximal tibia. [27] The tumor most commonly occurs in 
the femur (most tumors in the distal femur), in the tibia (most tumors in the proximal tibia) and in 
the humerus (most tumors in the proximal humerus). The other locations of the site of disease are 
in the pelvis, skull or jaw and ribs. [27] 
 
 
2.4.2 Age  
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There are large differences in the incidence rates of osteosarcoma in patients depending on age. 
[10] The incidence rate is higher in older children than in younger children. It occurs frequently in 
adolescents and children between the ages of 10-20 years old. [32] 
 
 
2.4.3 Gender 
 
The incidence rate of osteosarcoma is higher in males than in females with the rate being 5.4 per 
year per million males vs. 4.0 per year per million females. [27, 33] However, while the incidence 
rate is higher in males, the survival rate of osteosarcoma is higher in females.  
 
2.4.4 Diagnosis of Osteosarcoma 
 
The diagnosis of osteosarcoma requires the identification of malignant osteoblasts and neoplastic 
bone. [13] The diagnosis should be accurate as it is important that the patients are treated with 
specific protocols which have been associated with improved survival. [34-40] Osteosarcoma is 
mostly easily diagnosed by light microscopy, but its identification can be difficult due to various 
reasons such as the wide array of its histologic features might be mimicked by other primary and 
metastatic bone tumors etc. Another potential tool that can aid in the diagnosis of osteosarcoma 
could be immunohistochemistry. This is possible since osteoblasts are known to express specific 
marker proteins. The role of percutaneous image-guided biopsy in the diagnosis of bone-skeletal 
tumors have been well established [41-42] The placement of biopsy needles for the diagnosis are 
well aided and guided by the computed tomography and fluoroscopy. However, in recent times, 
non-invasive imaging techniques such as magnetic resonance imaging (MR) and ultrasonography 
(US) have been used for the guidance of the biopsies. [43-45] 
 
 
2.4.5 Potential therapeutic targets for the treatment of osteosarcoma 
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The microenvironment surrounding tumor cells has a significant impact on the phenotype, growth, 
invasiveness of malignant cells influencing metastatic properties and responses to drugs.    Recent 
examples of  potential therapeutic targets for treatment of the disease are the transmembrane 
surface receptors that have been implicated in tumorigenesis, [46] and it has been shown recently 
in other cancers that therapies targeted at transmembrane surface receptors have generated a 
substantial increase in both the quality of life and long-term survival. [47,48] Receptors such as 
human epidermal growth factor receptor HER-2, HER-3, HER-4, platelet-derived growth factor 
receptor (PDGFR)- β, c-Met, fibroblast growth factor receptor (FGFR)-2, FGFR-3, vascular 
endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, insulin like growth factor 
receptor 1 (IGF-1R), IGF-2R, insulin receptor (IR), and epidermal growth factor receptor (EGFR) 
have been shown to be expressed on several types of tumors as well as osteosarcoma. [49-51] It 
has been demonstrated that although insulin-like growth factor-2 receptor (IGF2R) is expressed 
normally across various tissue types, there has been an over-expression across a panel of 
osteosarcoma cell lines. [16] This constant over-expression of IGF2R may serve as a valuable 
therapeutic target for the treatment of osteosarcoma. In our earlier studies we have demonstrated 
the preferential tumor localization of the radiolabeled monoclonal antibody (mAb) to IGF2R in 
Osteosarcoma (OS) xenografts in mice in comparison with the control mAb. Additionally, we 
showed that treatment of OS tumors using Radiolabeled IGF2R- specific mAb MEM-238 resulted 
in tumor growth inhibition and possibly regression using a single administration and non-
optimized dosing in comparison with multiple controls [20]. The limitation of that work was the 
nature of MEM-238 mAb which binds only to human IGF2R thus precluding evaluation of mAb 
binding to IGF2R expressing healthy tissues as well as the use of one OS cell line. Recently, a 
novel murine mAb 2G11 that binds to both human and murine IGF2R became commercially 
available which was used in this study to evaluate the effectiveness of RIT.  
 
2.4.6 Prognosis and survival of patients with osteosarcoma 
 
Osteosarcoma is the most common non-haematopoietic cancer of the bone and has a poor 
prognosis in patients with relapse or recurrence [52-54]  
Some of the prognostic factors would be: 
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• Patients with osteosarcoma as a secondary neoplasm share the same prognosis as patients 
with newly diagnosed osteosarcoma if they are treated aggressively with surgical resection 
and chemotherapy. [55-58] 
• Patients belonging to the older adolescent and young adult age group, typically between 
the ages of 18 to 40 years tend to have a worse prognosis. [59-60] 
• Patients suffering from high grade osteosarcoma could be identified with  the laboratory 
tests such as LDH (Lactate Dehydrogenase) levels, alkaline phosphatase levels and 
histologic subtype. [61,59,6,62,63] 
• Body mass index: Patient with higher body mass index at the initial presentation 
have worse prognosis [64] 
 
2.5 Treatments for metastatic osteosarcoma  
 
Osteosarcoma is the most common malignant primary tumor of bone [65] and is characterized by 
the presence of metastases in a majority of patients. The cure of osteosarcoma in a sizable number 
of patients was reported consistently first in the 1970s and was achieved through the combination 
of surgical resection of tumors with multi-drug chemotherapy. [66] The results were improved 
further but since then no clinically significant advances have been made although many patients 
still access combination chemotherapy within and outside clinical trials. The number, site and size 
of the metastasis determine the overall management, prognosis and treatment of the disease. [67] 
Osteosarcoma is often treated with a combination of therapies that include surgery, chemotherapy 
and radiation therapy. Most patients with high grade tumors receive around three months of 
chemotherapy which is known as neo-adjuvant therapy. Today there has been an increasing focus 
on personalized medicine in therapy, exploiting antibodies that target cancer related antigens as  
one of the approaches. [65] The marketed immunotherapeutic antibodies targeting antigens such 
as HER2 and EGFR (trastuzumab and cetuximab) have been successful for treatment of other 
cancers and therefore could be of relevance for the targeted therapy of osteosarcoma. [68-70] 
Monoclonal antibodies (mAbs) by themselves can show antitumor activity but the effect is often 
clinically modest.  Because of this the  antibodies have been also conjugated to drugs, toxins or 
radionuclides to improve the efficacy. The use of antibody-toxin conjugates has previously been 
suggested as a modality in osteosarcoma. [71] Nanotechnology can potentially serve as a targeted 
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delivery vehicle which is capable of delivering large doses of radionuclides or chemotherapeutic 
agents into malignant cells and reduce the side-effects. 
 
2.5.1 Targeted drug delivery 
 
Radiolabeled nanocarriers can be designed and used for cancer diagnostic and therapeutic purposes 
when labelled with appropriate radionuclides. Targeted drug delivery systems such as radiolabeled 
nanocarriers have been developed to improve the biodistribution, pharmacology, toxicity and 
therapeutic properties of agents used in cancer diagnostics and therapeutics. [72] 
 
2.5.2 Nuclear medicine 
 
Millions of nuclear medicine procedures using radiopharmaceuticals are performed each year in 
more than 10,000 hospitals worldwide. The field of the nuclear medicine is evolving towards 
molecular medicine which is focusing more on the cellular and molecular pathways and 
mechanisms of disease. The most common radionuclide used in diagnosis is Technetium-99m. 
[73]  
Nuclear medicine plays a crucial role in the treatment of cancer by   helping to determine the extent 
or severity of the disease and by selecting the most effective therapy   based on the molecular 
properties of the tumor and the biological characteristics of the patient.  [74] 
 
2.5.3 Radionuclide therapy  
 
The selection of potential radionuclides for radionuclide therapy depends on the physical half-life, 
decay mode and the emission properties of the radionuclides. For targeted radionuclide therapy, 
the use of high and low energy β emitters as radioisotopes is ideal for the treatment of all sizes of 
tumor cells. The tissue penetration range (1-10mm) and cross-fire effect of β particles can kill the 
tumor cells in close proximity. The use of α-emitters holds great promise for the treatment of small 
cancer lesions and small-metastatic cancer due to their high linear energy transfer and tissue 
penetration range of 50-100 μm. [72] Radiopharmaceuticals   consist of two components: 1) 
Carrier and 2) Trace amount of radionuclide with a defined radiation type. [72] Biological carriers 
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in radiopharmaceuticals range from antibodies to  various proteins, peptides and nucleic acids.  
Production of a radiopharmaceutical must include a stable oxidation state, well defined 
coordination chemistry in an aqueous environment and relatively fast complexation kinetics at 
physiological pH. [75] The ideal radiopharmaceutical should deliver the radionuclide to the tumor 
tissue precisely with no radiation reaching the  healthy tissues. [72] The main characteristic of a 
radiopharmaceutical in oncology is a high ratio of activity accumulated per gram of tumor to the 
activity taken up per gram of tissue. The labelled agent should be retained in the blood for an 
optimal amount of time for reaching the tumors. The radiopharmaceutical must be excreted from 
the body rapidly to avoid accumulation in the gastrointestinal tract and kidneys. This is of 
importance since accumulation of the radionuclide in the gastrointestinal tract and kidneys leads 
to increased radiation dose to these organs. [76]  
 
2.5.4 Radioimmunotherapy 
 
Radioimmunotherapy (RIT) is a method of delivering cytotoxic radiation therapy in a targeted 
approach where an antigen-specific antibody is bound to either an alpha or beta- emitting 
radioisotope. [7,8] It combines the advantages of radiation therapy and specific delivery to the 
tumors  using mAbs. The therapeutic effect on the tumor tissue is achieved by absorption of the 
radiation energy   emitted by the radionuclides that are attached to the mAbs.  The choice of 
radionuclide for radioimmunotherapy depends on a number of characteristics such as: 1) Radiation 
characteristics of the radionuclide, 2) Radiolabeling chemistry and 3) Type of malignancy or cells 
targeted. [8] β-emitters are more suitable for targeting solid tumors because of their high energy 
and long path length whereas α-emitters are more suited for targeting single cells as in micro-
metastatic diseases etc. due to their high LET (Linear Energy Transfer) and short distance energy 
deposition (Fig.1). [74] RIT delivers cytocidal radiation to the targeted cell and is less affected by 
the multidrug resistance mechanisms in contrast to chemotherapy and does not depend on the 
immune system of a patient. It allows systemic administration, antibody-mediated specificity, and 
physical cytocidal damage in a manner which is well-tolerated by the patient. [20] 
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     Figure 2.1 Schematic diagram of tumor tissue penetration range of internal radiotherapy. [72] 
 
2.6 Nuclear imaging methods  
The diagnostic agents enhance the visibility of specific tissues by increasing the signal to noise 
ratio relative to surrounding tissues and are optimized to provide a quick, high-quality picture or 
image of the living system. Some of the imaging modalities are: MRI, CT, US, optical imaging, 
single photon emission computed tomography (SPECT) and positron emission tomography (PET) 
(Fig. 2). [77]  
 
2.6.1 Positron emission tomography (PET) 
PET provides information about the biochemical and physiological processes in the human body. 
For PET applications, positron emitting radionuclides are required such as F-18, C-11, N-13 and 
O-15. One of the most widely used radionuclides for PET imaging is Fluorine-18 (F-18) and 
because of its convenient half-life of 110 min. The radiopharmaceutical FDG-18 (please give the 
full name here)   is important for PET imaging in oncology. [78] 
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Fig 2.2 Typical molecular imaging instruments and images representative of each modality. [77] 
 
2.6.2 Single photon emission computed tomography (SPECT) 
The SPECT is a nuclear medicine tomographic technique using gamma rays wherein a SPECT 
scan analyzes the function of some of the internal organs. It forms a three-dimensional image of 
the distribution of gamma-emitting radiotracers injected into the body. An advantage of SPECT is 
that multiple probes when labelled with different isotopes may be studies in parallel since each is 
associated with its unique γ spectrum. [74] SPECT-CT combines anatomical and functional 
imaging and the images  from each modality are merged together. 
 
2.6.3 Internalization of antibodies into cancer cells 
To develop therapeutically potent anti-cancer antibody drugs such as antibody-drug conjugates 
(ADCs), it is important to identify antibodies that internalize into cells efficiently and not just bind 
to the antigens on the cell surface. Antibody internalization should be efficient as the delivery of 
cytotoxic drugs into the target cells is vital for the development of ADCs [79] The efficacy of 
ADCs depends not only on the binding affinity and specificity to the antigen, but also on the 
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internalization of the antibody into the cells.[80,81]  However, for radiolabeled antibodies the 
internalization  is NOT a vital requirement, as the beta or alpha particles travel certain 
distances, penetrate the cellular membrane and exert the damage on the cells. Nevertheless, 
internalization can contribute to the retention of the radionuclides within the tumor, which 
is important for longer lived radionuclides from the safety and efficacy point of view. 
 
3. Hypothesis 
 
We hypothesize that Lutetium-177 labelled IGF2R–specific monoclonal antibody will help to 
effectively target osteosarcoma tumor cells and that Lutetium -177 will be able to deliver high 
tumoricidal doses to the tumours without causing toxicity to healthy tissues. 
 
 
3.1 Objectives 
 
1) To evaluate the expression of IGF2R on commercial and patient derived osteosarcoma cell 
lines by flow cytometry and to select the cell lines for in vivo work. 
 
2) To perform biodistribution experiments with Indium-111 labeled IGF2R-specific 
monoclonal antibody in xenografted osteosarcoma tumors in SCID mice to evaluate the 
pharmacokinetics.  
 
3) To perform RIT experiments with Lutetium-177 labeled IGF2R-specific monoclonal 
antibody in xenografted osteosarcoma tumors in SCID mice to evaluate the efficacy and 
safety of the approach.  
 
4) To perform RIT experiment in murine osteosarcoma bearing immunocompetent C57Bl6 
mice to assess possible synergy or antagonism between RIT and functional immune 
system. 
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4. Materials and Methods 
 
4.1 Reagents and Antibodies 
 
MEM/EBSS medium that was supplemented with 10% Fetal Bovine Serum, 100 U Penicillin/0.1 
mg/ml Streptomycin, 1% Sodium Pyruvate solution and 1% Non-essential amino acids and 
Phosphatase buffered saline (1X), Trypsin 0.25% (1X) were purchased from HyClone, USA. A 
murine monoclonal IgG2a antibody 2G11 which binds to murine and human IGF2R and murine 
monoclonal IgG antibody MOPC-21 to be used as an isotype matching control were purchased 
from Invitrogen. MOPC-21 antibody was used as a negative control for the flow cytometry 
experiments, biodistribution experiment and therapy studies. MOPC-21 is produced by mineral oil 
induced plasmacytoma  tumor cell line, according to the manufacturer, The antigen for the 
antibody is unknown, but MOPC-21 has demonstrated negative binding after screening on a 
variety of resting, activated, live, and fixed murine and human tissues, and is widely used as non-
specific murine IgG control. (R)-2-Amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-
cyclohexane-1,2-diamine-pentaacetic acid (CHXA’’) bifunctional chelating agent (BCA) used for 
the conjugation of the antibody was purchased from Macrocyclics (USA). 111In was obtained from 
Nordion (Canada); 177Lu was purchased from RadioMedix (USA); and 225Ac/213Bi generator – 
from Oak Ridge National Laboratory (USA). Silica gel instant thin layer chromatography (SG-
iTLC) strips were obtained from Agilent (Canada). The internalization of the IGF2R specific 2G11 
monoclonal antibody into the 143B cell line was determined using the IncuCyte live-cell analysis 
system. The IncuCyte FabFluor Red Antibody Labeling Reagent for labeling the 2G11 antibody 
was  purchased from Sartorius.  
 
4.2 Cell Lines 
 
143B and SaOS2 are human osteosarcoma cell lines obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA). OS-17, OS-33 and OS-31 are well characterized patient-
derived osteosarcoma xenograft models maintained in our laboratories. [77] IGF2R is known to 
express normally across a wide array of tissue types but has shown constant over-expression in 
osteosarcoma cell lines. [16] These cell lines were cultured into a MEM medium that was 
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supplemented with 10% Fetal Bovine Serum, 100 U Penicillin/0.1 mg/ml Streptomycin, 1% 
Sodium Pyruvate solution and 1% Non-essential amino acids. The cells were grown under 
humidified conditions of 95% air and 5% CO2 at 37°C. Once confluent, cells were washed with 
PBS twice, trypsinized and re-suspended in media. The cell growth was monitored using a light 
microscope. An automated cell counter from Bio-Rad with cell counting slide was used to count 
the cells at different steps of the experiments.  
 
4.3 Measurement of IGF2R expression by Flow cytometry 
Basics of flow cytometry: Prior to testing  and even depending on the cells being analyzed, the 
sample may be treated with special dyes to further define cell sub-types. The dyes (fluorochromes) 
that are used are attached to monoclonal antibodies that bind to particular cells or key components 
of cells. In the instrument, the fluid in which the cells are suspended pass through very narrow 
channels so that the cells are organized in a single line as they pass the detectors. This is 
accomplished at a high rate (hundreds to thousands of cells per second.) The flow cytometer 
contains one or more lasers and a series of photodetectors that are able to identify certain 
characteristics unique to various cell types. The single cell suspension creates unique light 
shattering events that occur when each cell passes through the laser light. These initial events are 
characteristic of the size and shape of the cell, as well as the intensity of the signal that is generated 
by the specific dyes, thus creating patterns that reflect cell type. The signals from the detectors are 
then amplified and sent to a computer wherein  they are converted to digital read-outs displayed 
on a computer screen or in the form of a printout. [78] The Cytoflex flow cytometer instrument 
used has a computer software associated with it. The computer program controls the flow 
cytometer instrument during data acquisition where the parameters for measurement are selected. 
The acquisition conditions for the parameter measurement are selected based on the stopping rules 
such as the volume of the sample liquid aspirated, flow rate of the sample and number of events to 
be displayed for the cell populations which are entered into the software. Additionally, area, width 
or height on different parameters are selected as well. The data is generally presented in the form 
of graphs and histogram plots. Flow cytometry data analysis is based upon the principle of gating 
wherein the gates and regions are placed around populations of cells with common characteristics 
such as forward scatter, side scatter and receptor or marker expression to quantify and investigate 
the populations (cells) of interest. 
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Flow cytometry of osteosarcoma cell lines: This experiment was performed to assess the binding 
efficiency of the IGF2R specific monoclonal antibody 2G11 to the  osteosarcoma cells lines with 
the purpose of selecting the cell lines with the lowest and highest IGF2R expression for the follow-
up biodistribution studies. The osteosarcoma cell lines such as 143B, SaOS2, OS-17, OS-33 AND 
OS-31 were harvested, and cell numbers were determined by utilizing the cell counter followed 
by suspension in FACS buffer (100 μl). The cell suspension was distributed in a U-bottom 96 well 
plate with 5 ∗ 105 cells per well. Primary antibodies such as the IGF2R specific 2G11 and isotype 
matching control (negative control) MOPC-21 were added in a concentration of 1 μg/μl and cells 
were incubated on ice for 20 mins before 2 washes with  1 ml of FACS buffer. Secondary antibody 
anti-mouse IgG2a (APC) was added in a concentration of 1 μg/μl with 100 μl of FACS buffer to 
the cells and incubated for 20 mins and washed as in the previous step. The wash steps were 
performed by centrifugation at 500 g for 5 mins at 4°C. The cell pellets   were washed, taken  up 
in FACS buffer and analyzed in a Cytoflex flow cytometer instrument. This flow cytometry 
analysis was replicated three times for all the cell lines. The data was analyzed by the Flowjo 
software.  
Statistical Analysis: The statistics can be either be descriptive or inferential. The descriptive 
statistics allow us to describe our flow cytometry data and to test the hypothesis to check whether 
there is binding between the receptor IGF2R expressed by the cells and the IGF2R specific 
monoclonal antibody 2G11 and to see if there is an increase or decrease in the particular population 
of cells. 1.) Percentage of positive cells: If the cells that express the particular receptor or marker 
of interest are positive cells. Thus, we can say that those percentage of cells have positive and 
effective binding of the IGF2R specific monoclonal antibody 2G11 to the osteosarcoma cells. 2.) 
Measurement of median or mean of the distribution: These parameters are useful when comparing 
distribution of cells that overlap since we need to compare the entire population of cells and not 
just a part of it. 
 
4.4 Animal model 
The animal work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board (AUP 20170006)  and adhered to the Canadian Council on Animal Care guidelines for 
humane animal use. 
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Cell lines were grown in Eagle’s Minimum Essential medium and supplemented with 10% FBS, 
Sodium pyruvate, Non-essential Amino acids and Pen/strep. The cells were grown in a 
humidified condition of 95% air and 5% CO2 at 37°C. Once confluent, cells were washed PBS 
twice, trypsinized and resuspended in media. Approximately 3 million cells in 100 μL of Eagle’s 
Minimum Essential medium were implanted per animal. 
 
1)Tumor bearing mouse model: Six to eight weeks old female SCID (CB17/Icr-
Prkdcscid/IcrIcoCrl) mice obtained from Charles River Laboratories (USA) were anesthetized with 
isoflurane and injected subcutaneously with three million of either 143B or OS-17 cells into the 
right flanks.  
 
2)Tumor monitoring: After 143B and OS-17 cells   were implanted into the mice, tumors were 
allowed to grow until palpable and measuring approximately 5 mm in diameter. Tumor volume 
was calculated every 3 days until the desired volume of the tumor (50-100 mm3) was achieved.   
Electronic calipers were utilized to measure the length and width of the tumor. Volume was 
calculated utilizing the formula (V= L*W^2/2). It was noticed that for the mice injected with the 
143B cell line around 80% of the mice developed palpable tumors by day 12 and for the OS-17 
cell line by day 5.  
 
4.5 Conjugation of Bifunctional Chelating agent CHXA’’ to mAB’s  
 
For radiolabeling with 111In, the antibodies were first conjugated to a bifunctional chelator, 
CHXA”. The bifunctional chelator CHXA” was added to the antibody at 5 molar equivalents 
excess of 2 mg/ml solution. Five mL of 10X conjugation buffer (0.05 M Carbonate/Bicarbonate, 
0.15 M NaCl, 5 mM EDTA, pH 8.6 - 8.7) was combined with 0.5 M EDTA, pH = 8.0 (0.5 mL) 
and was diluted to 50 mL in a 50 mL Falcon tube with deionized water to give the 1X buffer.  An 
Amicon Ultra 0.5 mL centrifugal filter (30K MW cut off, Fisher) was loaded with 2 mg of either 
2G11 or MOPC-21 antibody.  The antibody was exchanged into the above conjugation buffer by 
 20 
performing 6 x 1.5 mL washes using an Amicon concentrator in a refrigerated centrifuge at 4oC. 
A solution of bifunctional CHXA” ligand with 2 mg/mL concentration was prepared by dissolving 
CHXA” in conjugation buffer. The antibody was recovered from the Amicon and 23.6 µL of 2 
mg/mL CHXA” solution in conjugation buffer is added to provide 5-fold molar equivalents  excess 
of CHXA” over the antibody.  The reaction mixture was incubated at 37oC for 1.5 hrs. The reaction 
mixtures were then purified into 0.15 M ammonium acetate buffer, pH=6.5-7.0, with 6 x 1.5 mL 
washes on Amicon concentrators in a refrigerated centrifuge at 4oC. The sample were stored at 
4oC.  A Bradford assay was performed to determine protein recovery and concentration. 
 
4.6 Radiolabeling of antibodies 
 
The IGF2R-specific mAb 2G11 and the isotype matching control mAb MOPC21 were then 
labelled with the radioisotope 111In to yield 111In-2G11 and  111In-MOPC-21, and with 177Lu  to 
yield 177Lu-2G11 and 177Lu-MOPC-21,  or with 213Bi to yield 213Bi-2G11. The radiolabeling of an 
antibody-CHXA” conjugate with 111In was performed to achieve the specific activity of 
approximately 5 µCi/µg of the antibody. For example, 600 µCi of 111In chloride was added to 10 
µL 0.15 M ammonium acetate buffer and added to a microcentrifuge tube containing 120 µg 2G11-
CHXA” conjugate in 0.15 M ammonium acetate buffer. The reaction mixture was incubated for 
60 min at 37oC, and then the reaction was quenched by the addition of 3 µL 0.05 M EDTA solution. 
The percentage of radiolabeling was measured by SG-iTLC using 0.15 M ammonium acetate 
buffer as the eluent. SG-iTLCs were cut in half and read on a Perkin Elmer 2470 Automatic 
Gamma Counter (top containing unlabeled 111In, bottom containing antibody conjugated 111In). 
177Lu labeling was performed with an identical protocol using 177Lu as the radioisotope and 
labeling with 213Bi was carried out as in (79). Both 111In and 177Lu incorporation was >95%. The 
antibody was labelled with 111In radionuclide for the biodistribution study since it has a physical 
half-life of 2.8 days and is widely used as a radiotracer for various diagnostic applications. 
 
4.7 Biodistribution Study 
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The biodistribution was performed to assess whether IGF2R- specific mAb 2G11 will localize in 
the tumor preferentially when compared to non-specific isotypes matching control MOPC-21.  
As murine and human IGF2R are not similar, the mAb 2G11 was used since it can bind to both 
human as well as murine IGF2R. The IGF2R-specific mAb 2G11 and isotype matching control 
mAb MOPC-21 were radiolabeled with 111In as above. Mice were separated into two different 
groups according to the cell lines i.e. 143B and OS-17. Tumors were allowed to grow until they 
reached an average size of 70-100 mm3. The volume was calculated assuming elliptical geometry 
and using the following formula: V = (LxW2)/2. The mice in each group were then randomized 
and administered with 20 μCi each via an intraperitoneal injection, with 18 mice (8 mice implanted 
with OS-17 cell line and 10 mice implanted with 143B cell line) receiving 111In- 2G11 and 16 mice 
(8 mice implanted with OS-17 cell line and 8 mice implanted with 143B cell line) receiving 111In- 
MOPC-21. At 24 and 48 hr. post injection mice were sacrificed from each group: 143B tumor 
bearing mice injected with 111In- 2G11 or MOPC21, and OS17 tumor bearing mice injected with 
111In- 2G11 or MOPC21. Once sacrificed, the tumor, blood, heart, lungs, pancreas, spleen, kidney, 
liver, brain, a section of the small and large intestines, thigh muscle, and femur were collected, 
weighed, and counted in a gamma counter (Perkin Elmer). The percent of injected dose per gram 
(%ID/g) for each sample was calculated to determine the biodistribution.  
 
4.8 MicroSPECT/CT IMAGING (micro single photon emission computed tomography/computer 
tomography) 
 
The images were collected on a MILabs VECTor4 (Netherlands) microSPECT/CT scanner and 
processed using the comprehensive image analysis software package PMOD (version 3.9, PMOD 
Technologies, Inc, Switzerland).  Imaging studies were conducted using 200 μCi 111In at a 5:1 
mCi/mg specific activity with a CHXA’’ conjugated 2G11. Tumor-bearing mice were 
administered 111In- 2G11 via IP injection and imaged in the prone position at 2, 24, and 48 hours 
post injection. SPECT data was collected for 20 minutes using an Extra Ultra High Sensitivity 
Mouse (XUHS-M) collimator for 20-350 keV range using spiral trajectories. All SPECT images 
were reconstructed using both 245 keV and 171 keV 111In gamma emissions on a 0.4 mm voxel 
grid with MILabs reconstruction software. 
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4.9 Radioimmunotherapy Study 
 OS17 and 143B Tumor bearing mice were monitored until the tumor size reached 70-100 mm3. 
The mice were randomized into groups of 5 mice per group. Group 1 received 80 μCi 177Lu-2G11, 
group 2 - 80 μCi 177Lu-MOPC-21, group 3 - unlabeled (cold) 2G11, and group 4 was left untreated. 
In addition, a group of mice  with 143B tumors was given 80 μCi 213Bi-2G11. Tumors were 
monitored as previously described and average tumor volume was calculated for the mice in each 
group over a 12-day period. At the completion of the observation period the mice were humanely 
sacrificed, their spleens removed and analyzed histologically for signs of radiation damage. Their 
blood was analyzed for AST, ALT, BUN and creatinine as biomarkers of possible liver and kidney 
toxicity.   
 
4.9.1 Internalization Assay 
The internalization of the IGF2R specific 2G11 monoclonal antibody into the 143B cell line was 
determined using the IncuCyte Antibody Internalization Assay provided by Essen Biosciences 
(Sartorius). The cells of the 143B cell line were typically seeded at 50 μL/well, with 5,000-30,000 
cells/well into a 96-well plate and were left to adhere for between 2-24 hours.  The 2G11 antibody 
was then mixed with the IncuCyte FabFluor Red Antibody Labeling Reagent purchased from 
Sartorius for labeling the antibody with the regent. They were mixed at a molar ratio of 1:3 in 
DMEM media with a 2x final assay concentration. The mixture was incubated for 15 mins to allow 
conjugation. This IncuCyte FabFluor-labeled Antibody was then added to the cell plate at 50 
μL/well and the images were captured every 15-30 mins in the IncuCyte live-cell analysis system. 
These images were analyzed using the same integrated software. Subsequently the graphs 
representing internalization of the IGF2R specific 2G11 monoclonal antibody into the 143B cells 
was obtained with the  GraphPad prism statistical software. To enable the quantitative 
measurement of labeled antibodies, assays based on the internalized fluorescence pH sensitive 
fluorescent dyes have been developed.  Those dyes are  used for labeling the antibodies specific 
for the targeted receptor. This pH sensitive dye can be helpful in monitoring the internalization 
quantitatively over time. When internalization is measured by a single step labeling protocol, the 
Fc-targeted Fab coupled pH-sensitive dye (IncuCyte FabFluor) is used for tagging the antibody of 
interest. These pH sensitive dyes are non-fluorescent at neutral pH and exhibit increasing 
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fluorescence as the pH become more acidic in the endocytic compartment. However, the relatively 
small increase in fluorescence over the cellular pH range in question limits their applicability. 
[82,83]  The assay developed by Sartorius which we utilized in this work,  measures internalization 
with high specificity, sensitivity and morphological information.  However, there are certain 
limitations of this approach, such as high background fluorescence, quenching of the fluorescent 
dyes over time, etc. which often limit the use of this technique to the qualitative only evaluation 
of  internalization. 
 
4.9.2 Statistical Analysis  
The differences between the biodistribution groups were analyzed using Kruskal-Wallis and/or 
Mann-Whitney tests. Differences between the treatment groups were similarly analyzed using the 
Kruskal-Wallis and/or Mann Whitney tests.  
 
 
5.0 Results  
 
5.1 IGF2R Expression in human Osteosarcoma cell lines 
 
2G11 mAb specifically binds to IGF2R-expressing cell lines and preserves its immunoreactivity 
post-conjugation of the bifunctional chelating agent. We first sought to establish if 2G11 mAb to 
human and murine IGF2R would specifically bind to OS across multiple cell lines. We utilized 
flow cytometry technique to analyze the expression of IGF2R across two standard cell lines from 
ATCC such as 143B and SaOS2 and three patient-derived cell lines such as OS17, OS31 and 
OS33. The 2G11 mAb bound specifically to all 5 cell lines when compared with the isotype 
matching control mAb MOPC21 (Fig 3 a-e.). The expression of IGF2R by ATCC cells lines 
SaOS2 and 143B was 1.5-2 times higher than that of the patient-derived osteosarcoma cell lines. 
Of the patient-derived cell lines, OS17 had the lowest expression of IGF2R (Fig. 3e) and OS33 
exhibited the highest (Fig. 3c).  
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a)                                           b)                                           c) 
 
      d)                                            e)  
 
Fig 5.1 Flow cytometry detection of IGF2R expression on 5.1.1) 143B, 5.1.2) SaOS2, 5.1.3) OS-
33, 5.1.4) OS-31 and 5.1.5) OS-17 cell lines.   
On comparing the binding results between the cell lines, we selected 143B and OS-17 as the cell 
lines with highest and lowest IGF2R expression respectively. We further used these cell lines for 
the biodistribution and RIT experiments. 
 
Isotype Control Ab 
Background staining 
IGF2R Specific Ab 
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Fig 5.2  Average median value calculated for each cell line on the basis of the values calculated 
from the flow cytometry experiment.    
 
5.2 Binding of conjugated and unconjugated 2G11 antibody to  OS-17 and 143B cells   
To enable the radiolabeling of 2G11 monoclonal antibody with 111In (111Indium) for biodistribution 
and imaging study, 2G11 was conjugated to the bifunctional chelating agent CHXA”. The flow 
cytometry experiment was carried out to demonstrate that after conjugating 2G11 with CHXA” it 
was still able to bind to 143B and OS-17 cells to the same extent as the naked 2G11 monoclonal 
antibody.  
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            Fig 5.3 Binding of conjugated and unconjugated antibody 2G11 mAb to OS-17 cells.  
 
 
 
 Sample ID Count 
 OS-17 2G11 CHXA 8024 
 OS-17 2G11 8077 
 OS-17 MOPC-21 CHXA 8067 
 OS-17 MOPC-21 8223 
 OS-17 8214 
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       Fig 5.4 Binding of conjugated and unconjugated antibody 2G11 mAb to 143B cells. 
 Sample ID Count 
 143B 2G11 CHXA 8581 
 143B 2G11 8544 
 143B MOPC-21 CHXA 8473 
 143B MOPC-21 8497 
 143B 8439 
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5.3 Biodistribution of 111In – labeled monoclonal antibodies in 143B and OS-17 osteosarcoma 
xenografts 
 
 
To find out if 2G11 mAb is capable of selectively targeting IGF2R-expressing osteosarcoma 
tumors, this mAb and the isotype matching murine mAb MOPC21 were radiolabeled with the 
imaging radionuclide 111In and administered by intraperitoneal injection to 143B and OS17 
tumor-bearing mice. The mice were sacrificed at 24 and 48 hours after the administration of the 
radiolabeled mAbs and the biodistribution was performed. The results are shown in Fig 7a and 7b. 
The uptake of 2G11 mAb in the tumors at 24 and 48 hours was significantly higher than that of 
MOPC-21 for both the types of tumors. Some uptake of MOPC-21 control mAb in the tumors  can 
be explained by the enhanced permeability and retention (EPR) effect  by which molecules of 
certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate 
in tumor tissue much more than they do in normal tissues. The uptake of IGF2R specific 2G11 
mAb into the tumors was relatively similar for both cell lines with the uptake in the tumor being 
slightly but not significantly for the OS-17 cell line tumors. There was a very high uptake of the 
IGF2R specific 2G11 mAb in the spleens of mice with both tumor types in comparison to the 
isotype control MOPC-21.  
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Fig 5.5 Biodistribution of 111In – labeled monoclonal antibodies in OS-17 xenografts at 48 hours 
post antibody administration.  
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Fig 5.6 Biodistribution of 111In – labeled monoclonal antibodies in OS-17 xenografts at 24 hours 
post antibody administration. 
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Fig 5.7 Biodistribution of 111In – labeled monoclonal antibodies in 143B xenografts at 48 hours 
post antibody administration.  
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Fig5.8 Biodistribution of 111In – labeled monoclonal antibodies in 143B xenografts at 24 hours 
post antibody administration.  
 
 
5.4 microSPECT/CT imaging of 111In–labeled monoclonal antibodies in 143B and OS-17 
osteosarcoma xenografts 
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The microSPECT imaging of OS17 tumor-bearing mice is shown in Fig. 8a and 143B tumor-
bearing mice is shown in Fig. 8b. The imaging was done at 2, 24 and 48 hours post administration 
of the radiolabeled 2G11 mAb. At 2 hours post administration, the mAb was still circulating in the 
blood and through the organs with the tumors practically not visible, at 24 hours the tumors were 
clearly visible, and the spleens were visible as well. By 48 hours, the mAb cleared almost 
completely from the circulation with only the tumors and the spleens retaining high amounts of 
the 2G11 mAb.  To find out if this high uptake of 2G11 mAb in the spleen was due to the possible 
metastatic spread of tumor cells into the spleen, we performed microSPECT/CT imaging of the 
healthy SCID mice with radiolabeled 2G11 mAb  at 2 and 24 hours and 4 days post mAb 
administration (Fig. 9). High spleen uptake was seen in the images starting at 24 hours, confirming 
that the 2G11 mAb was binding to the IGF2R expressed by the spleen cells of SCID mice.           
 
 
                                                                                                        
                  
2 HOURS                        24 HOURS                    48 HOURS  
 
Fig 5.9 microSPECT imaging of OS17 tumor-bearing SCID mice labelled with 111Indium-CHXA” 
2G11. The red arrow indicates the spleen and the blue arrow indicates the tumor in the image of 
the mouse post 48 hours.   
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2 HOURS                             24 HOURS                      48 HOURS  
 
Fig 5.10 microSPECT imaging of 143B tumor-bearing SCID mice labelled with 111Indium-
CHXA” 2G11. The red arrow indicates the spleen and the blue arrow indicates the tumor in the 
image of the mouse post 48 hours. 
 
              
2 HOURS                     24 HOURS                4 DAYS 
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Fig 5.11 microSPECT imaging of healthy SCID mice with radiolabeled 2G11 mAb. The arrow 
pointing to the organ in the image post 24 hours is the spleen of the healthy SCID mouse.  
 
 5.5 IGF2R expression in murine osteosarcoma cell line 
 
We set out to establish if 2G11 mAb specific for human and murine IGF2R would specifically 
bind to the murine osteosarcoma cell line K7M2. For this purpose, we utilized flow cytometry 
technique to analyze the expression of IGF2R on K7M2 cells when compared to 143B cell line as 
a positive control.  On analyzing the results, the K7M2 cell line showed no IGF2R expression. 
 
 
 Sample ID Count 
 K7M2 2G11 1µg/µl 7340 
 K7M2 MOPC-21 1µg/µl 7175 
 K7M2  7150 
 143B 2G11 1µg/µl 8553 
 36 
         
         Fig 5.12 IGF2R expression by K7M2 cell line at 1μg/μl concentration  
 
 
        Fig 5.13 IGF2R expression by K7M2 cell line at 5μg/μl concentration 
 143B MOPC-21 1µg/µl 8517 
 143B 8134 
 Sample ID Count 
 K7M2 2G11 5µg/µl 7478 
 K7M2 MOPC-21 5µg/µl 7147 
 K7M2  7150 
 143B 2G115µg/µl 8594 
 143B MOPC-21 5µg/µl 8523 
 143B 8134 
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5.6 Radioimmunotherapy (RIT) with radiolabeled 2G11 mAb significantly slowed down the 
growth of OS-17 and 143B OS tumors  
 
To investigate if radiolabeling 2G11 with therapeutic radionuclides will confer therapeutic 
properties, we radiolabeled it with an intermediate energy beta-emitter 177Lu. Pilot experiments 
demonstrated that the maximum tolerated dose for 177Lu-2G11 is below 250 μCi, and in the follow 
up experiments the mice were given IP either 80 μCi 177Lu-2G11, 80 μCi 177Lu-MOPC-21, 
unlabeled (cold) 2G11, or were left untreated. Administration of 177Lu-2G11 significantly (P<0.05) 
slowed down the growth of both 143B (Fig. 12a) and OS17 tumors (Fig. 12b) in comparison with 
the untreated tumors and cold 2G11. The treatment effect was IGF2R-specific as the control mAb 
MOPC-21 radiolabeled with the same activity of 177Lu, had significantly less effect on the tumor 
growth rate. In addition, a group of mice with 143B tumors received 80 μCi of the alpha-emitter 
213Bi-2G11 mAb, and its retardation effect on the tumor growth became more profound, though 
not significantly, than that of 177Lu-2G11 by day 12 post treatment. RIT treatment of tumors 
resulted in tumors developing necrosis by day 12 and necessitated euthanizing the animals in 
compliance with the Animal Research Ethics regulation. 
a)                                                                          
 
Fig 5.14 Radioimmunotherapy of OS tumor-bearing SCID mice: a) 143B tumors. The mice were 
given IP either 80 μCi 177Lu-2G11, or 80 μCi 177Lu-MOPC-21 or left untreated. A group of mice 
were also given 80 μCi 213Bi-2G11. 
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                   b) 
                             
 
  
 
Findings demonstrate that neither 177Lu-2G11 nor 213Bi-2G11 produced histologically overt 
splenic damage (Fig. 12a-12b). The levels of liver enzymes (ALT and AST) as well as of creatinine 
and BUN were within the normal range for SCID mice (Fig. 15a-g) attesting to the high tolerability 
of RIT.  
a)                                             b)                                                   c) 
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Fig 5.14 Radioimmunotherapy of OS tumor-bearing SCID mice: b) OS17 tumors. The mice were given 
IP either 80 μCi 177Lu-2G11, or 80 μCi 177Lu-MOPC-21, or unlabeled (cold) 2G11, or was left untreated.                                                                      
 
 
Fig 5.15 Hematologic toxicity was evaluated in 143B tumor bearing mice treated with 177Lu-2G11 and  
Untreated after Radioimmunotherapy. a) White blood cells (WBC), b) Red blood cells (RBC) and c) 
Platelets (PLT) were analyzed after 1 week using the automated blood analyzer. There was a four-fold 
decrease in the counts which were well within the limits attesting to the high tolerability of RIT. 
The ranges given above were provided by the Charles River Laboratories.  
 
 
WBC :1.36 - 5.42(109/L) 
RBC :  9.39 – 12.64 (1012/L) 
PLATELET : 733 – 1441 (109/L) 
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a)                                           b)                                                     c 
 
 
  
              
 
 
 
 
 
 
a) b) 
 
     
 
WBC :1.36 - 5.42(109/L) 
RBC :  9.39 – 12.64 (1012/L) 
PLATELET : 733 – 1441 (109/L) 
Fig 5.16. Hematologic toxicity was evaluated in OS-17 tumor bearing mice treated with 177Lu-
2G11 and  Untreated after Radioimmunotherapy. a) White blood cells (WBC), b) Red blood cells 
(RBC) and c) Platelets (PLT) were analyzed after 1 week using the automated blood analyzer. 
There was a four-fold decrease in the counts which were well within the limits attesting to the high 
tolerability of RIT.  
The ranges given above were provided by the Charles River Laboratories. 
 40 
 
 
 
 
c)                                                     d) 
                           
   
 
 
 
                       e)                                                          f) 
 
ALT : 35 –  121 (U/L) 
AST : 55 – 278 (U/L) 
CREATININE : 17.6803 – 44.2008 (µmol/L) 
BLOOD UREA NITROGEN (BUN) : 5.3571 – 10.7143 (mmol/L) 
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                      g)                                                        h)  
 
 
 
 
 
 
 
 
 
 
 
 
5.7 Internalization Assay  
 
We utilized the IncuCyte Antibody Internalization Assay to determine the internalization of the 
IGF2R specific 2G11 monoclonal antibody into the 143B cell line. The method allows the antibody 
to be screened for their internalization properties. This method uses pH sensor dyes which are low 
in fluorescence at neutral pH but become highly fluorescent at acidic pH. For receptor mediated 
ALT : 35 –  121 (U/L) 
AST : 55 – 278 (U/L) 
CREATININE : 17.6803 – 44.2008 (µmol/L) 
BLOOD UREA NITROGEN (BUN) : 5.3571 – 10.7143 (mmol/L) 
Fig 5.17 Evaluation of the liver and kidney toxicity for the 143B tumor bearing mice:  a) Alanine 
aminotransferase (ALT); b) Aspartate aminotransferase (AST) ;  c) Creatinine ; d) Blood Urea 
Nitrogen (BUN) and OS-17 tumor bearing mice: e) Alanine aminotransferase (ALT) f) Aspartate 
aminotransferase (AST) g) Creatinine h) Blood Urea Nitrogen (BUN). There was a four-fold 
decrease in the counts which were well within the limits attesting to the high tolerability of RIT. 
 
The ranges given above were provided by the Charles River Laboratories. 
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internalization, the antibody against the particular receptor is conjugated with the pH sensor dye 
and incubated with the cells expressing the receptor. When this antibody labeled with the pH sensor 
fluorescent dye binds to its antigen (receptor) on the cancer cells, they do not become fluorescent 
but when internalization into the endosomal and lysosome vehicles takes place, the pH drops and 
the dye becomes fluorescent. It follows the process from early endosomes (pH 6.3) to lysosomes 
(pH 4.7). The IncuCyte FabFluor Red Antibody was tested at a final concentration of 4 μg/ml and 
was incubated for 15 mins at 37°C in dark for conjugation. This labelled antibody was added to 
the 143B cells and was analyzed using the  IncuCyte live-cell analysis system. On analyzing the 
results, the 143B cells showed positive internalization of the IGF2R specific 2G11 monoclonal 
antibody. (Fig 16a) A positive result is indicated when the cells present in the well emit a red 
fluorescent light showing that the receptor mediated antibody is being internalized into the cells. 
Fig 16b shows the image for the non-specific control MOPC-21 that was used for comparison to 
the IGF2R specific 2G11 monoclonal antibody. Fig 16c indicates a graphical representation of the 
internalization of the IGF2R specific 2G11 monoclonal antibody into the 143B cells. The images 
were captured at the end of 48 hours to check for the internalization and the graphs  were  plotted 
using the values obtained at the end of 48 hours.  
 
 
      
Fig 5.18 143B Cells stained with 2G11               Fig 5.19 143B Cells stained with MOPC-21 
 
IGF2R is mostly intracellular and gets cycled between the surface and internally as a transport 
mechanism. The reason it remains on the surface of the cancer cell is still unclear and additional 
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experiments such as CRISPR-CAS9 experiments are now being   performed to test  if absence of 
IGF2R will affect cellular proliferation (Dr. David Geller, personal communications).  
 
 
Fig 5.20 Graphical representation of the internalization of the IGF2R specific 2G11 monoclonal 
antibody into the 143B cells.  
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Fig 5.21 Concentration dependent internalization of the IGF2R specific 2G11 monoclonal 
antibody into the 143B cells.  
 
5.8 Biodistribution of different excess molar equivalents concentrations of a DOTA conjugated 
monoclonal antibody in tumor free mice 
 
To find out whether Human IgG A’ (Propriety Antibody) conjugated at different molar 
equivalents excess concentrations of  bifunctional chelating agent DOTA will display the same 
biodistribution in healthy mice. The antibodies were conjugated at 10 molar equivalents and 109 
molar equivalents excess of DOTA and the biodistribution experiment was performed at four 
different time points for each of the excess concentrations of DOTA. The CB17 black mice were 
divided into two groups with one group receiving the 10 molar equivalents excess DOTA 
conjugated antibody and the other group receiving 109 molar equivalents excess DOTA 
conjugated antibody. The mice were sacrificed at 4, 24, 48 and 96 hours after the administration 
of the 225Ac -radiolabeled  mAbs and the biodistribution was performed. The results are shown in 
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Fig 16e. The uptake of the 10 molar equivalents excess conjugated Hum195 mAb was significant 
in the organs at 4 and 24 hours however by 48 hours and 96 hours the Human IgG ‘A’ started to 
excrete out from the body. The uptake of the 109 molar equivalents excess conjugated Human 
IgG ‘A’ was relatively similar with a slight difference in the excretion out of the organs but not 
significantly. The main difference was really fast clearance of 109 molar equivalents excess 
conjugate from the blood, which might have implications for the tumor uptake in future studies 
in mouse tumor models. 
 
 
Fig 5.22 Biodistribution of 225 Ac – labeled Human IgG ‘A’ at 10 molar equivalents excess 
concentration of DOTA  
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Fig 5.23 Biodistribution of 225 Ac – labeled Human IgG ‘A’ at 109 molar equivalents excess 
concentration of DOTA 
 
6.0 Conclusion  
In conclusion, given the lack of new effective therapies RIT might prove beneficial. Since 
IGF2R is expressed normally across various tissue types, the constant over-expression in 
Osteosarcoma recommends that it may serve as a valuable therapeutic target in the treatment of 
Osteosarcoma. Through the study, it was shown that Radioimmunotherapy with the use of both 
the 177Lu-2G11 mAb conjugate and the alpha emitting 213Bi-2G11 mAb conjugate showed 
substantial reduction in the tumor growth rate in vivo using both the patient derived cell line as 
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well as the standard derived cell line. The selective targeting of the radionuclides such as 
Lutetium-177 or Bismuth-213 to the cancer cell antigen IGF2R using 2G11 monoclonal 
antibodies exhibited a great potential in treating the tumors.  
Future Work   
This radiolabeled monoclonal antibody hence can be used in the development of a therapeutic 
agent for the treatment of Osteosarcoma. In addition, as there are overwhelming similarities 
between human and canine osteosarcomas [96] -  presence of IGF2R in canine tumors helps to 
further develop IGF2R-targeting RIT of OS using the comparative oncology approach.  
 
 
6.1 Discussion  
This study demonstrates the feasibility of targeting OS using a commercially available mAb to 
IGF2R within a xenografted murine model.  Biodistribution and microSPECT/CT imaging reveal 
ed selective uptake of the radiolabeled IGF2R-specific mAb 2G11 within the tumor as well as the 
spleen, with the latter resulting in no detectable untoward effect within the experimental time 
course.   Moreover, the treatment using both the beta emitting 177Lu-2G11 mAb conjugate and the 
alpha emitting 213Bi-2G11 mAb conjugate showed substantially slowed tumor growth in vivo using 
both a standard cell line and a PDX tumor line.  No local or systemic toxicity was noted.  
 
Use of the beta-emitting radionuclide, 177Lu (maximum beta energy 0.13 MeV) offers multiple 
benefits over 188Re, which was previously utilized.  Firstly, 177Lu has a longer physical half-life of 
6.7 days, extending the therapeutic effect for a longer period. Secondly, the process of labeling 
177Lu is simpler and more reliable [84]. Finally, 177Lu is readily available from several vendors, 
likely is due to the recent approval of the 177Lu-labeled peptide (Lutathera) in Europe and the 
United States for the treatment of somatostatin receptor positive neuroendocrine tumors. 
Importantly, our laboratory has recently demonstrated the equivalency of 188Re- and 177Lu-labeled 
mAbs in the treatment of experimental cervical cancer [85]. Taken together, the use of 177Lu 
appears to support the treatments’ technical feasibility and clinical translation. Additionally, while 
previous work has demonstrated tight Ab binding to IGF2R, Scatchard plot analysis has shown 
only a moderate number of available IGF2R binding sites.  Antibodies labeled with alpha emitters 
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are, at least theoretically, less dependent on the antigen density as one or two hits of an alpha-
particle can kill a cell. [7]   
The biodistribution and microSPECT/CT imaging experiments in the two OS xenograft models 
showed high IGF2R-specific uptake of 111In-2G11 in the tumors that was not dependent on the in 
vitro levels of IGF2R expression by the respective cell line. This observation suggests that even 
tumors with lower IGF2R expression will be effectively targeted with the IGF2R-specific mAb. 
The uptake of 111In-2G11 into the tumors at both 24 and 48 hrs was significantly higher than the 
previously observed uptake of 188Re-MEM-238 [20]. This might be due to the residualizing nature 
of trivalent radiometals such as 111In or 177Lu that tend to remain in the tumor even after separating 
from the mAb, as opposed to 188Re, which leaves the tumors relatively fast after oxidizing into the 
inert perrhenate anion. The high uptake of radiolabeled 2G11 mAb into tumors translated into an 
impressive therapeutic response for both OS17 and 143B xenograft models. Interestingly, a very 
short-lived alpha-emitter 213Bi (46 min physical half-life versus 6.7 days for 177Lu) had a similar 
effect to 177Lu treated mice for the 143B tumor xenografts, highlighting the enormous therapeutic 
potential of alpha-emitters in RIT. 
While systemic chemotherapy combined with wide surgical resection remains the mainstay of OS 
treatment [13], there remains no meaningful alternative therapy for those patients who relapse 
following standard first-line therapy. The addition of conventional cytotoxic chemotherapy to the 
standard three-drug backbone consisting of high-dose methotrexate, doxorubicin and cisplatin, has 
failed to increase overall survival.  This stark reality underscores the need for innovative disruptive 
approaches to OS therapy, particularly for patients who present with overt metastases or who 
relapse following standard therapy. While OS has been historically considered a radiation-resistant 
histology, the entire radiation oncology field has enjoyed numerous advances and improvements.  
Currently, the application of radiation therapy has been well-established in specific instances. For 
example, patients unable to undergo an R0 resection, particularly in the spine and in the pelvis, 
benefit from the addition of external beam radiation, realizing improved outcomes when compared 
with chemotherapy alone [86, 87]  External beam radiation also offers a well-tolerated palliative 
option in cases where cure is no longer feasible and where the main treatment objective shifts to 
improving pain control and quality of life.   
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Radionuclide therapy has been utilized for the management of metastatic disease to the bone in 
both the setting of carcinoma and OS.  Both Samarium-153 and Radium-223 localize to areas of 
increased bone turnover, thereby delivering relatively high doses of selective treatment and 
yielding a reduction in pain and a decrease in analgesia dependence in a number of prospective 
double-blinded placebo-controlled randomized studies. [88-91] However, these 
radiopharmaceuticals are only used for the palliation of painful bone metastases and are not viewed 
as standard of care. Combination of radionuclide and monoclonal antibodies is a recognized 
strategy used for a number of hematopoietic and solid tumors, combining the targeted specificity 
of the monoclonal antibody with cytotoxic impact exerted by the radionuclide. [92]  This approach 
may offer further benefit via the abscopal effect, a well-recognized phenomenon, described as a 
radiation-mediated tumor response in disease outside of or distant from the field of radiation.    
Limitation of the current study includes the relatively short experimental time course, which 
resulted from the need to euthanize the animals owing to local tumor ulceration despite tumor 
response.  It is unclear if this simply represents the natural course of a growing tumor or a 
treatment-related event and further characterization of tumor histology may offer insight.  The use 
of immunocompromised animals is an inherent limitation in that it discounts or artificially nulls 
any immune-mediated response.  For this reason and despite being a recognized model, it simply 
does not recapitulate the human condition.  Planned utilization of murine OS within an 
immunocompetent murine model was not feasible, given the lack of IGF2R overexpression within 
murine OS.  Taken together, these limitations illustrate the need for improved preclinical models 
which allow for the evaluation of human tumor within immune-intact animals. The observation of 
high spleen uptake of 111In-2G11 during biodistribution and microSPECT/CT imaging of OS 
tumor-bearing and healthy SCID mice raised the concern about potential undesirable effects of 
RIT on this organ and may represent a translational limitation despite the histological splenic 
analysis which failed to demonstrate any evidence of organ injury. 
As with all therapeutic measures, safety remains a paramount and critical consideration.  In 
addition to the normal splenic histology, no abnormalities in the liver enzymes and kidney 
biomarkers such as creatinine and BUN were detected. It has been shown that 2G11 mAb was able 
to mimic the effect of mannose-6-phosphate on the receptor up-regulation. [93] As 2G11 stays in 
circulation for several days, it upregulates the IGF2R expression in the tumor and the spleen, which 
results in its increased uptake in those tissues. Interestingly, according to [93] mAb MEM-238 
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which was also used in our initial RIT of OS experiments [20] does not upregulates IGF2R. This 
observation can explain why the tumor uptake of radiolabeled MEM-238 at 48 hours was only 
3.5% ID/g, while the uptake of 2G11 at 48 hours in the current study was 5 times higher at 18% 
ID/g. These findings corroborate the Human Atlas Database contention that IGF2R is only 
minimally or moderately expressed in all normal organs, suggesting that using it as a target for 
RIT should be relatively safe: https://www.proteinatlas.org/ENSG00000197081-IGF2R/tissue. 
For comparison, SSTR1, which is targeted by the recently approved Lutathera, is highly expressed 
in several crucial organs and is still safe to administer to patients: 
https://www.proteinatlas.org/ENSG00000139874-SSTR1/tissue. 
Safety can be further demonstrated within the context companion animals, which serve as a great 
resource, as shown by the remarkable growth of comparative oncology over the last 30 years. In 
this regard, canine and human OS share certain antigens and can be targeted with the same mAbs 
[94], and the mAbs to human cation independent mannose-6-phosphate receptor also bind to 
canine one. [95] In fact, a sequence alignment of human, mouse and canine IGF2R genes 
encompassing the IGFII binding region (containing domains 11-FNII), shows that this region is 
highly conserved across these species with 82% sequence identity. Randomly selected cases of 
canine OS from the companion dogs treated in our institution, demonstrated significant expression 
of IGF2R (unpublished data). As there are overwhelming similarities between human and canine 
osteosarcomas [96] -  presence of IGF2R in canine tumors sets the stage of further development 
of IGF2R-targeting RIT of OS using the comparative oncology approach. 
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